KR850001739A - 티아졸리딘 유도체의 제조방법 - Google Patents

티아졸리딘 유도체의 제조방법 Download PDF

Info

Publication number
KR850001739A
KR850001739A KR1019840005314A KR840005314A KR850001739A KR 850001739 A KR850001739 A KR 850001739A KR 1019840005314 A KR1019840005314 A KR 1019840005314A KR 840005314 A KR840005314 A KR 840005314A KR 850001739 A KR850001739 A KR 850001739A
Authority
KR
South Korea
Prior art keywords
benzyl
hydroxy
ylmethoxy
group
thiazolidine
Prior art date
Application number
KR1019840005314A
Other languages
English (en)
Other versions
KR890000370B1 (ko
Inventor
다까오(외 4) 요시오까
Original Assignee
가와무라 요시부미
상꾜 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가와무라 요시부미, 상꾜 가부시끼가이샤 filed Critical 가와무라 요시부미
Publication of KR850001739A publication Critical patent/KR850001739A/ko
Application granted granted Critical
Publication of KR890000370B1 publication Critical patent/KR890000370B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음

Description

티아졸리딘 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. (a) 하기 일반식(Ⅱ)의 할로프로피온산 유도체를 티오우레아와 반응시켜 하기일반식(Ⅲ)의 화합물을 제조하고,
    (b) 필요하다면, 상기 화합물을 가수분해(선택적)하여 하기일반식(Ⅰ)의 화합물을 제조하고,
    (c) 임의로, W가 ＞C=O기를 나타낼 때, 상기 단계(a) 또는 단계 (b)에서 제조된 화합물을 환원시켜 W가 ＞CH-OH기를 나타내는 화합물을 제조하고,
    (d) 임의로, W가 ＞CH=OH기를 나타낼 때, 이 화합물을 아실화하여 W가 ＞CH-OH6'의 기(식중 R6는 수소원자를 제외하고 R6에서 정의한 바와 같다)를 나타내는 화합물을 수득하고,
    (e) 필요하다면, 생성물을 염화시킴을 특징으로 하는 하기일반식(Ⅰ)의 화합물 및 약학적으로 수용할 수 있는 그의 염의 제조방법.
    [상기 식들중, R1및 R2는 같거나 서로 다르며, 각각 수소원자 또는 C1~C|5아킬기를 나타내고, R3는 수소원자, C1~C5지방족아실기, 지환족아실기, 방향족아실기, 복소환아실기, 아르지방족아실기,(C1~C6알콕시) 카르보닐기 또는 아르알킬옥시카르보닐기를 나타내며;R4및 R5는 같거나, 서로 다르고 각각 수소원자, C1~C|5아킬기 또는 C1~C5알콕시기를 나타내거나, R4및 R5는 함께 C1~C4알킬렌디옥시기를 나타내며;n은 1,2 또는 3이고; W는 -CH2-, ＞CO 또는 ＞CH-OR6기(R6는 R3에서 정의한 원자 또는 기중의 하나를 나타내며, R3과 같거나 서로 다를 수 있다)를 나타내며; Y 및 Z는 같거나 서로 다르고 각각 산소원자 또는 이미노(=NH)기를 나타내며; X는 할로겐원자를 나타내고; A는 시아노기, 카르복시기, 알콕시카르보닐기, 카르바모일기 또는 일반식 -COO(M)m의 기(M은 양이온을 나타내고, m은 양이온 M의 원자가의 역수를 나타낸다)를 나타낸다]
  2. 제1항에 있어서, 단계(a)의 반응이 유기용매존재하에 수행되는 방법.
  3. 제1항에 있어서, 단계(b)의 가수분해가 용매 및 유기산 또는 무기산 중에서 수행되는 방법.
  4. 제1항에 있어서, 단계(c)의 환원이 보로하이드라이드에 의해 수행되는 방법.
  5. 제1항에 있어서, 단계(d)의 아실화가 산할라이드 또는 산수물에 의해 수행되는 방법.
  6. 제1항에 있어서, 단계(e)의 염화가 알칼리금속, 알칼리토금속 또는 3가의 금속의 수산화물 또는 알콕시드에 의해 수행되는 방법.
  7. 제1항에 있어서, 단계(a)의 반응이 유기용매 존재하에 수행되고, 단계(b)의 가수분해가 용매 및 유기산 또는 무기산 중에서 수행되고, 단계(c)의 환원이 브로하이드라이드에 의해 수행되고, 단계(d)의 아실화가 산할라이드 또는 산수물에 의해 수행되고, 단계(e)의 염화가 알칼리금속, 알칼리토금속 또는 3가의 금속의 수산화물 또는 알콕시드에 의해 수행되는 방법.
  8. 제1항에 있어서, 화합물(Ⅰ)이 5-[4-(6-히드록시-2,5,7,8-테트라메틸크로만-2-일 메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(2-에틸-6-히드록시-5,7,8-트리메틸크로만-2-일 메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-5,7,8-트리메틸크로만-2-일 메톡시)벤질]티아졸리딘-2,4-디온, 5-{4-[2-(6-히드록시-2,5,7,8-테트라메틸크로만-2-일) 에톡시]벤질}티아졸리딘-2,4-디온, 5-{4-[2-(7-t-부틸-6-히드록시-2-메틸크로만-2-일)에톡시]벤질}티아졸리딘-2,4-디온, 5-{4-[2-(6-히드록시-7,8-디메톡시-2,5-디메틸크로만-2-일)에톡시]벤질}티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2,7-디메틸크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2-이소부틸-,5,7,8-트리메틸크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2,5,7,8-테트라메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(7-t-부틸-6-히드록시-2-메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(2-에틸-6-히드록시-5,7,8-트리메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(6-히드록시-5,7,8-트리메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(6-히드록시-2,7-디메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(6-아세톡시-2,5,7,8-테트라메틸크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온 5-[4-(6-부티릴옥시-2,5,7,8-테트라메틸크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(2,5,7,8-테트라메틸-6-니코티노일옥시크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2,5,7,8-테트라메틸-4-옥소크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(7-t-부틸-6-히드록시-2-메틸-4-옥소크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2-이소부틸-5,7,8-트리메틸-4-옥소크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2-이소부틸-5,7,8-트리메틸--4-옥소크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-히드록시-2-이소부틸-5,7,8-트리메틸-4-옥소크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(7-t-부틸-6-히드록시-2-메틸-4-옥소크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온,5-[4-(6-히드록시-2-이소부틸-5,7,8-트리메틸-4-옥소크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-[4-(6-아세톡시-2,5,7,8-테트라메틸-4-옥소크로만-2-일메톡시)벤질]티아졸리딘-2,4-디온, 5-[4-(6-아세톡시-5,7,8-트리메틸크로만-2-일메톡시)벤질]-2-이미노티아졸리딘-4-온, 5-{4-[2-(6-아세톡시-7-t-부틸-2-메틸크로만-2-일)에톡시]벤질}-2-이미노티아졸리딘-4-온, 5-{4-[2-(6-아세톡시-7,8-디메톡시-2,5-디메틸크로만-2-일)에톡시]벤질}-2-이미노티아졸리딘-4-온 및 그의 약학적으로 수용할 수 있는 염의 군에서 선택된 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840005314A 1983-08-30 1984-08-30 티아졸리딘 유도체의 제조방법 KR890000370B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP158375/83 1983-08-30
JP158375/1983 1983-08-30
JP58158375A JPS6051189A (ja) 1983-08-30 1983-08-30 チアゾリジン誘導体およびその製造法

Publications (2)

Publication Number Publication Date
KR850001739A true KR850001739A (ko) 1985-04-01
KR890000370B1 KR890000370B1 (ko) 1989-03-15

Family

ID=15670325

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005314A KR890000370B1 (ko) 1983-08-30 1984-08-30 티아졸리딘 유도체의 제조방법

Country Status (12)

Country Link
US (1) US4572912A (ko)
EP (1) EP0139421B1 (ko)
JP (1) JPS6051189A (ko)
KR (1) KR890000370B1 (ko)
AT (1) ATE33838T1 (ko)
AU (1) AU570067B2 (ko)
CA (1) CA1263395A (ko)
DE (1) DE3470742D1 (ko)
DK (1) DK164701C (ko)
ES (1) ES8607297A1 (ko)
FI (1) FI80693C (ko)
IE (1) IE58036B1 (ko)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189B2 (ja) * 1980-07-21 1985-11-12 株式会社日立製作所 磁気バブル駆動回路
JPS60226873A (ja) * 1984-03-28 1985-11-12 Sankyo Co Ltd １，３−ベンゾオキサチオ−ル誘導体及びその製法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH0653738B2 (ja) * 1985-02-26 1994-07-20 三共株式会社 チアゾリジン誘導体
US4703052A (en) * 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
JPS62234085A (ja) * 1985-12-18 1987-10-14 Sankyo Co Ltd チアゾリジン誘導体を有効成分とする糖尿病性合併症治療剤
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
JP2574845B2 (ja) * 1987-02-04 1997-01-22 三共株式会社 チアゾリジン化合物
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US5260294A (en) * 1988-08-09 1993-11-09 Hoffman-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
US5132310A (en) * 1988-08-09 1992-07-21 Hoffmann-La Roche Inc. Pharmacologically active chromanes
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
CA2071629C (en) * 1990-02-09 1997-12-30 Jerry R. Colca Use of insulin sensitizing agents to treat hypertension
ATE205206T1 (de) * 1990-04-27 2001-09-15 Sankyo Co Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
CA2082003A1 (en) * 1991-11-20 1993-05-21 David Laffan Process for the preparation of substituted pentaalkylchromenes
AU671811B2 (en) * 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
NO302519B1 (no) * 1991-12-26 1998-03-16 Sankyo Co Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat
CA2089012A1 (en) * 1992-02-21 1993-08-22 Josef Heveling Process for the preparation of 6-hydroxy-2,5,7,8-tetra- alkyl-2-(4-aminophenoxymethyl) chromans
CA2089013A1 (en) * 1992-02-21 1993-08-22 Josef Heveling Process for the preparation of 6-hydroxy-2, 5, 7, 8- tetraalkyl-2-(4-aminophenoxymethyl) chromans
DE69326736T2 (de) * 1992-08-31 2000-06-08 Sankyo Co Oxazolidin-Derivate mit Antidiabetika und Anti-Fettleibigkeit-Eigenschaften, ihre Herstellung und therapeutische Verwendung
JPH0631079U (ja) * 1992-09-22 1994-04-22 沖電線株式会社 シート付き小型ｓｍｔコネクタ
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
AU749416B2 (en) * 1993-09-15 2002-06-27 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
DK0684242T3 (da) 1993-12-27 1999-11-01 Japan Tobacco Inc Isoxazolidindionderivat og anvendelse deraf
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
JPH11510508A (ja) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
IN182496B (ko) * 1996-02-20 1999-04-17 Reddy Research Foundation
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
CA2251468A1 (en) * 1996-04-04 1997-10-16 Sankyo Company, Limited Phenylalkylcarboxylic acid derivatives
ATE231136T1 (de) * 1996-04-09 2003-02-15 Reddys Lab Ltd Dr Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften, verfahren zu deren herstellung und pharmazeutischen zusammenstellungen, die sie enthalten
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
DE19619819A1 (de) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
AU3091197A (en) * 1996-05-16 1997-12-05 Boehringer Mannheim Gmbh New process for preparing troglitazone
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
CZ298812B6 (cs) * 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
PL331148A1 (en) * 1996-07-12 1999-06-21 Smithkline Beecham Plc Novel method of treating the leptin immunity
CA2265656A1 (en) * 1996-09-12 1998-03-19 Sankyo Company, Limited Glutathione reductase activity potentiator containing troglitazone
US6121288A (en) * 1996-11-08 2000-09-19 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
PL337510A1 (en) 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
FR2766820B1 (fr) * 1997-07-31 1999-10-22 Rhodia Chimie Sa Procede de preparation de 2h-1-benzopyranes et intermediaires de synthese utiles dans la mise en oeuvre du procede
BR9813019A (pt) 1997-10-02 2000-09-05 Sankyo Co Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas
EP0916665A1 (de) * 1997-11-11 1999-05-19 Lonza A.G. Verfahren zur Herstellung von Chromanderivaten
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
WO1999030739A1 (fr) * 1997-12-16 1999-06-24 Sankyo Company, Limited Remede contre la leucemie
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
BR9908911A (pt) 1998-03-19 2001-10-02 Bristol Myers Squibb Co Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade
WO2000007582A2 (en) * 1998-08-06 2000-02-17 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
WO2000010994A1 (en) * 1998-08-19 2000-03-02 Sankyo Company, Limited Process for the preparation of 2-(aryloxymethyl)-2,5,7,8-tetramethylchroman-6-ols
HUP0104108A2 (hu) 1998-09-17 2002-03-28 Bristol-Myers Squibb Company Eljárás diabétesz kezelésére egy aP2 inhibitor vagy kombinációja alkalmazásával
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
RU2256661C2 (ru) 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
SK2102003A3 (en) 2000-08-07 2003-08-05 Ranbaxy Signature Llc Liquid formulation of metformin
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002083066A2 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
MXPA03010867A (es) * 2001-05-29 2004-02-27 Kyoto Pharma Ind Nuevos derivados heterociclicos y uso farmaceutico de los mismos.
KR100898358B1 (ko) * 2001-05-29 2009-05-20 교토 야쿠힝 고교 가부시키가이샤 신규 복소환 화합물 및 그 의약 용도
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2003084517A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
WO2003096548A2 (de) * 2002-05-14 2003-11-20 Siemens Aktiengesellschaft Verfahren zum erzeugen eines sendesignals
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
JP2006516620A (ja) * 2003-01-24 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー 甲状腺受容体におけるシクロアルキル含有アニリドリガンド
EP2669377A3 (en) * 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006017292A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20070259928A1 (en) * 2004-12-13 2007-11-08 Taishi Yoshida Medicinal Composition for Treating Diabetes
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7238702B2 (en) * 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
WO2006097809A2 (en) * 2005-03-18 2006-09-21 Orchid Chemicals & Pharmaceuticals Limited Novel tyrosine derivatives
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
CA2617102A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US20080064884A1 (en) * 2006-05-10 2008-03-13 Astrazeneca Ab Novel Process 1
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MX356965B (es) 2007-04-11 2018-06-21 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009058944A2 (en) 2007-11-01 2009-05-07 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PA8855701A1 (es) * 2008-12-23 2010-07-27 Análogos de nucleósidos
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
EA019341B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
KR20170093264A (ko) 2009-03-11 2017-08-14 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2914250B1 (en) 2012-11-05 2018-04-04 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2015054500A2 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
AU2015335603B2 (en) 2014-10-24 2020-04-30 Bristol-Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432660A (en) * 1973-10-30 1976-04-22 Science Union & Cie Piperazine derivatives processes for their preparation and and pharamacueitcal compositions containing them
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE3115152A1 (de) * 1981-04-15 1982-12-02 Hoechst Ag, 6000 Frankfurt "heterocyclische phenylether und diese enthaltende herbizide mittel"
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
HU194214B (en) * 1983-02-15 1988-01-28 Alkaloida Vegyeszeti Gyar Process for producing 7-alkoxy-2h-chromene derivatives and insecticide and nematocide compositions containing them as active components

Also Published As

Publication number Publication date
IE842217L (en) 1985-02-28
FI80693C (fi) 1990-07-10
IE58036B1 (en) 1993-06-16
EP0139421B1 (en) 1988-04-27
CA1263395A (en) 1989-11-28
FI843422A (fi) 1985-03-01
AU570067B2 (en) 1988-03-03
EP0139421A1 (en) 1985-05-02
US4572912A (en) 1986-02-25
DK164701C (da) 1992-12-21
ES8607297A1 (es) 1986-05-16
DE3470742D1 (en) 1988-06-01
FI843422A0 (fi) 1984-08-30
KR890000370B1 (ko) 1989-03-15
DK415184D0 (da) 1984-08-30
AU3255984A (en) 1985-03-07
FI80693B (fi) 1990-03-30
DK164701B (da) 1992-08-03
ATE33838T1 (de) 1988-05-15
JPH0231079B2 (ko) 1990-07-11
ES535552A0 (es) 1986-05-16
DK415184A (da) 1985-03-01
JPS6051189A (ja) 1985-03-22

Similar Documents

Publication Publication Date Title
KR850001739A (ko) 티아졸리딘 유도체의 제조방법
KR860003243A (ko) 타아졸리딘디온 유도체의 제조방법
CY2393B1 (en) Process for preparing 4-(2-(2-pyridyl)ethoxy)benzaldehyde derivatives.
KR960702460A (ko) 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them)
EP0337704A3 (en) Beta-lactam derivatives
KR910011816A (ko) 세로토닌 길항질, 그의 제조 및 그를 함유하는 조성물
KR870003100A (ko) 벤즈이미다졸 유도체
IE791851L (en) 4-(naphthylmethyl) piperidine derivatives
KR890014520A (ko) 이소인돌리논 유도체, 그 제조방법 및 이를 함유한 약품
KR970006302A (ko) 4-아미노-3-아실나프티리딘 유도체
KR840004076A (ko) 티오메틸 파리딘 유도체의 제조방법
ES8602811A1 (es) Un procedimiento para preparar un compuesto cefemico
KR860000303A (ko) 세펨 화합물의 제조방법
KR840001166A (ko) 스피로티아졸리딘일 피페라진 유도체 제조방법
US4563534A (en) Process for producing 2-(2-aminothiazol-4-yl)glyoxylic acid derivative or a salt thereof, and intermediates therefor and process for producing the intermediates
ES2070101A1 (es) Procedimiento para la preparacion de derivados de cefem.
KR850007977A (ko) 세펨화합물의 제조방법
CA1339369C (en) Antiulcer 1-benzimidazolyl-pyridinium salt and pharmacological composition containing the same
KR840005092A (ko) 벤조페논 유도체의 제조방법
KR860008172A (ko) 1,3,4-티아디아졸 유도체의 제조방법
KR930019620A (ko) 4-치환된 아제티디논 유도체의 제조방법
ES8105981A1 (es) Procedimiento para la preparacion de derivados de 4-(nafta- leniloxi)piperidina
JPS5564586A (en) Thiazolidine derivative
JPS5754177A (ja) Chikanchiazoorujudotai
KR880006215A (ko) 티아졸 화합물의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19971020

Year of fee payment: 16

EXPY Expiration of term